551 related articles for article (PubMed ID: 16815689)
1. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
[TBL] [Abstract][Full Text] [Related]
2. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
3. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
4. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
7. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML
Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546
[TBL] [Abstract][Full Text] [Related]
8. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.
Roberts JA; Boots R; Rickard CM; Thomas P; Quinn J; Roberts DM; Richards B; Lipman J
J Antimicrob Chemother; 2007 Feb; 59(2):285-91. PubMed ID: 17135183
[TBL] [Abstract][Full Text] [Related]
9. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
10. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
11. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872
[TBL] [Abstract][Full Text] [Related]
13. Daily serum piperacillin monitoring is advisable in critically ill patients.
Blondiaux N; Wallet F; Favory R; Onimus T; Nseir S; Courcol RJ; Durocher A; Roussel-Delvallez M
Int J Antimicrob Agents; 2010 May; 35(5):500-3. PubMed ID: 20226635
[TBL] [Abstract][Full Text] [Related]
14. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
Jaruratanasirikul S; Sriwiriyajan S; Ingviya N
J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion.
Langgartner J; Lehn N; Glück T; Herzig H; Kees F
Chemotherapy; 2007; 53(5):370-7. PubMed ID: 17785973
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
Patel GW; Patel N; Lat A; Trombley K; Enbawe S; Manor K; Smith R; Lodise TP
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):236-40. PubMed ID: 19500529
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
[TBL] [Abstract][Full Text] [Related]
19. A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study.
Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Udy AA; Paul SK; Lipman J; ;
Crit Care Resusc; 2013 Sep; 15(3):179-85. PubMed ID: 23944203
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
